35 results about "Benzoates" patented technology

A method of synthesizing the benzoate salt of 5-MeO-DMT comprising the step of treating the hydrochloride salt of 5-MeO-DMT with a base, prior to the addition of benzoic acid.

A method of synthesizing the benzoate salt of 5-MeO-DMT comprising the step of treating the hydrochloride salt of 5-MeO-DMT with a base, prior to the addition of benzoic acid.

A method for making the benzoate salt of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]-2-fluoro-benzonitrile, designated compound (A), and methods for using compound (A) are provided.

To provide a pharmaceutical composition for preventing or treating cognitive dysfunction.SOLUTION: The pharmaceutical composition contains benzoic acid or a benzoic acid salt.SELECTED DRAWING: None

The invention discloses a preparation method of a high-quality perovskite thick film for an X-ray detector, and relates to the technical field of radiation detection materials and devices. The preparation method of the thick film comprises the following steps: preparing a precursor solution from lead iodide, cesium iodide, formamidine iodide, methylamine iodide, 4-guanidinobenzoic acid hydrochloride, N, N-dimethylformamide and acetonitrile; a bulk phase functional additive is introduced to optimize a large number of Schottky defects at the grain boundary of the perovskite thick film; depositing onto a heated conductive glass substrate using a spray coating technique; and in combination with a low-temperature solvent atmosphere annealing process, secondary growth of crystal grains and grain boundary healing are promoted, and a large-area polycrystalline thick film can be obtained.

A method for reducing fouling in a styrene production process, the method comprising the steps of introducing an additive into a stream containing styrene and a byproduct, divinylbenzene (DVB), wherein the additive comprises at least one compound comprising one or more functional groups selected from the group consisting of amines, alcohols, aminoalcohols, labile C-C, esters, carbamates, aldehydes, ketones, acids, acetates, benzoates, labile hydrogen, and combinations thereof, and having a boiling point greater than or equal to 170°C and within ±10°C, ±20°C, ±30°C, ±40°C, ±50°C, or ±60°C of the boiling point of divinylbenzene (DVB), which is 195°C, wherein the at least one compound is effective in inhibiting crosslinking of the divinylbenzene (DVB). A system for performing the method is also provided.

The invention provides various salt forms of deuterated dextromethorphan as shown in a formula (I) as well as a preparation method and application of the various salt forms. The various salt forms comprise tartrate, citrate, hydrobromide and benzoate. Also provided are various crystal forms of the above salts. The salt has excellent effects in the aspects of stability, biological activity, bioavailability, drug effect and the like, and is suitable for development of pharmaceutical preparations.

To provide a crystal of 2 - (4-acetylbenzyl) - 3 - ((4-fluorophenyl) amino) - 577 - trimethyl-7, 8-dihydro-pyrazolo-imidazo [1, 2-a] 2H [4, 3-e] pyrimidin-4 (5H) - one.SOLUTION: Provided is a crystal of an acid addition salt form selected from, for example, succinate form, citrate form, adipate form, tartrate form (e.g., L-tartrate form), malate form, gluconate form (e.g., D-gluconate form), maleate form, fumarate form, aspartate form (e.g., L-aspartate form), hippurate form, sebacate form, glycolate form, galactarate form, benzoate form, pamoate form, oxalate form and malonate form.SELECTED DRAWING: None

Provided herein are methods relating to the purification of a polypeptide comprising an Fc region (e.g., an antibody) via protein A chromatography; methods relating to the use of a wash solution comprising a benzoate salt and / or benzyl alcohol during protein A chromatography; and methods of adjusting a harvest using sodium benzoate prior to protein A chromatography.

Provided are a salt and / or a crystal form of a compound degrading BTK and preparation and application thereof. The pharmaceutically acceptable salt and crystal form of the compound as shown in formula (I), wherein the pharmaceutically acceptable salt is selected from a maleate salt, a fumarate salt, a hydrogen halide salt (preferably a hydrobromide salt and a hydrochloride salt), a sulfate salt, a phosphate salt, an L-tartrate salt, a citrate salt, an L-malate salt, a hippurate salt, a D-glucuronate salt, a glycolate salt, a mucate salt, a succinate salt, a lactate salt, an orotate salt, a pamoate salt, a glycine salt, an alanine salt, an arginine salt, a cinnamate salt, a benzoate salt, a benzene sulfonate salt, a p-toluene sulfonate salt, an acetate salt, a propionate salt, a valerate salt, a triphenylacetic acid salt, an L-proline salt, a ferulic acid salt, a 2-hydroxyethanesulfonate salt, a mandelate salt, a nitrate salt, a methanesulfonate salt, a malonate salt, a gentisate salt, a salicylate salt, an oxalate salt or a glutarate salt:

This invention relates to novel 2-(1-hydroxypentyl)benzoate, its preparation method, and its applications. Specifically, it relates to a cycloalkanamine 2-(1-hydroxypentyl)benzoate with the structure shown in Formula I, its preparation method, pharmaceutical compositions with the compound as the active ingredient, and the application of the compound in the treatment and / or prevention of ischemic cardiovascular and cerebrovascular diseases, especially mild, moderate, and severe acute ischemic stroke.

The present invention relates to the field of chemical pharmaceutical technology, and specifically discloses a preparation method of nafamostat mesylate. 6-amidino-2-naphthol mesylate, p-guanidinobenzoic acid hydrochloride and EDCI are added to a first solvent to carry out a condensation reaction; then a saturated sodium bicarbonate aqueous solution is added to obtain an intermediate; the intermediate is added to a second solvent, and then methanesulfonic acid is added to form a salt, and purified to obtain nafamostat mesylate. EDCI first reacts with the first solvent to be activated, and the oxygen atom on the carbonyl carbon of the carboxylic acid is positively charged in the activated EDCI, thereby increasing the electrophilicity of the carboxylic acid and forming an active intermediate, making it easier for it to undergo a nucleophilic substitution reaction with an alcohol, and undergoing dehydration condensation to form an ester bond. The present invention uses EDCI as a condensing agent, improves the production efficiency and yield of nafamostat mesylate, improves the purity of nafamostat mesylate, reduces the impurity content, and is low in cost and easy to industrialize.

The invention belongs to the technical field of agricultural biology, and particularly relates to application of ningnanmycin salt to prevention and treatment of tobacco mosaic virus diseases. Derivatives of ningnanmycin salts are developed on the basis of ningnanmycin, and the derivatives comprise ningnanmycin acetate, ningnanmycin lactate, ningnanmycin phosphate, ningnanmycin sulfate, ningnanmycin citrate, ningnanmycin benzoate, ningnanmycin oxalate, ningnanmycin hydrochloride, ningnanmycin nitrate and the like. When the ningnanmycin salts are applied to prevention and treatment of the tobacco mosaic viruses, experiments show that compared with ningnanmycin, the ningnanmycin salts have the advantages that the prevention and treatment effect on the tobacco mosaic viruses is remarkably improved, the prevention and treatment effect of moroxydine hydrochloride can be achieved or even exceeded, and the application prospect is good.

The present invention provides methods of preparing compound of Formula (I), wherein the compounds are represented by the structure of Formula (I) wherein: R1 each is independently F, Cl, Br, I, OCH3, CN or NO2; R2 each is independently identical or different C1-C5 alkyl; n1 is an integer between 1 and 5; and n2 is an integer between 1 and 4. In addition, the present invention provides a compound represented by the following structures: Compound (1a) and Compound (2), wherein X comprises: chloride, acetate, adipate, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydroiodide, maleate, 2-hydroxyethanesulfonate, lactate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, sulfonate, tartrate, thiocyanate, toluenesulfonate, or undecanoate salt, or any combination thereof.

The present invention provides a plurality of salt forms of deuterated dextromethorphan represented by formula (I), a preparation method therefor and a use thereof. The deuterated dextromethorphan salt comprise tartrate, citrate, hydrobromate and benzoate. Also provided are a plurality of crystal forms of the salt. The salt exhibits excellent stability, bioactivity, bioavailability, medicinal effect and the like, and is suitable for development of pharmaceutical formulations.

This application discloses a traditional Chinese medicine oral ulcer patch containing camellia oil and its preparation method, belonging to the field of traditional Chinese medicine technology. The traditional Chinese medicine oral ulcer patch containing camellia oil, by weight fraction, comprises: 7.1-9.1 parts camellia oil, 5-7 parts propolis, 2-4 parts Bletilla striata extract, 2-4 parts honeysuckle extract, 2-4 parts Artemisia argyi volatile oil, 4.4-6.4 parts collagen peptides, 14-16 parts polyvinyl alcohol, 4-6 parts hydroxypropyl methylcellulose, 4-6 parts glycerin, 1-3 parts polyethylene glycol, 0.2-0.4 parts benzoate, 0.1-0.3 parts menthol, and 0.5-1.5 parts vitamin E. This traditional Chinese medicine oral ulcer patch not only has anti-inflammatory effects, relieves oral ulcer pain, and promotes ulcer healing, but also forms a stable protective film layer in the oral cavity, effectively isolating external stimuli such as food friction and saliva erosion, providing a stable microenvironment for mucosal repair.

The present disclosure provides a method of preventing or treating cognitive dysfunction in a subject in need thereof, including administering to the subject an effective amount of a benzoic acid salt.

A method of producing cyclohexane-1-carboxylate (CHC), including providing a growth medium comprising a yeast extract, and a crotonate salt; providing a culture of Syntrophus aciditrophicus (S. aciditrophicus); using the growth medium to initiate growth of the culture of S. aciditrophicus; after the S. aciditrophicus has initiated cell division, adding to the growth medium a benzoate salt, wherein after an incubation period, the CHC produced by the culturing of the S. aciditrophicus in the growth medium is purified. The incubation period may be continued until the amount of CHC in the growth medium has achieved a concentration of at least 1 g / l (7.8 mM).

The application discloses a preparation method of a naphthomostat mesylate impurity standard substance, and specifically comprises the following steps: firstly, reacting m-aminobenzoic acid with a hydrochloric acid solution to obtain an m-aminobenzoic acid hydrochloride solution; then, adding a magnetic solid acid catalyst and a 20-30% mass concentration cyanamide aqueous solution, and stirring and reacting at room temperature under a pulse magnetic field to obtain 3-guanidinobenzoic acid hydrochloride; then, adding 3-guanidinobenzoic acid hydrochloride, 6-amidino-2-naphthol mesylate, N,N'-dicyclohexyl carbodiimide and a supported catalyst into pyridine, stirring and reacting at room temperature to obtain 6-amidino-2-naphthyl-3-guanidinobenzoic acid ester; and finally, salifying to obtain 6-amidino-2-naphthyl-3-guanidinobenzoic acid ester mesylate. The 6-amidino-2-naphthyl-3-guanidinobenzoic acid ester mesylate with high purity and high yield obtained by the application is of great significance for the quality research of naphthomostat mesylate.

The present application belongs to the technical field of mining, and particularly relates to a leaching agent and application thereof, and a method for exploiting ion-type rare earth ore. The leaching agent provided by the present application comprises a main leaching agent and an auxiliary leaching agent; the auxiliary leaching agent is a benzoate salt having the same cation as the main leaching agent. The present application uses the leaching agent to leach ion-type rare earth ore, and the obtained rare earth leaching mother liquor and a precipitant are mixed to perform precipitation, and then solid-liquid separation is performed to obtain supernatant and rare earth precipitate, respectively; the supernatant is recycled and used as water for preparing the leaching agent; the rare earth precipitate is subjected to acid dissolution with hydrochloric acid, and then solid-liquid separation is performed to obtain a chlorinated rare earth solution and benzoic acid; the obtained benzoate salt can be reused as the auxiliary leaching agent by mixing the benzoate salt with an alkaline solution to perform a neutralization reaction. The present application can efficiently leach rare earth while effectively inhibiting aluminum leaching, and the leaching agent ions that are not used during leaching can be returned to the mine for reuse, thereby avoiding the introduction of new non-rare earth impurities in the process of exploiting ion-type rare earth while inhibiting aluminum.

There is provided an aerosolisable formulation comprising (i) caffeine; (ii) a solvent selected from water, propylene glycol, glycerol and mixtures thereof; and (ill) a buffer comprising benzoic acid and a benzoate.

Disclosed in the present invention is a palladium-catalyzed coupling reaction of a secondary propargyl benzoate to a sulfonamide, which realizes highly selective synthesis of a 2-amino-substituted conjugated diene. The method is suitable for the coupling of a series of functionalized propargyl benzoates and sulfonamides, and enables late-stage functionalization modification of complex small-molecule drugs, which provides a new method for synthesizing a sulfonamide compound containing a conjugated diene structure, and has significant application prospects.

A quinazoline derivative (represented by the formula (I)) salt's crystal form, a preparation method and application are provided; specifically, the hydrochloride crystal form A, B, C, D, F, H, I, Sulphate crystal form A, Maleate crystal form A, Succinate crystal form A, Adipate crystal form A, Glycolate crystal form A, Malate crystal form A, Fumarate Salt crystal form A, besylate crystal form A, B, C, benzoate crystal form A, hippurate crystal form A and oxalate crystal form A of the quinazoline derivative represented by formula (I). The salt crystal form provided by the present invention has good stability, which can be used in the treatment of non-small cell lung cancer brain metastasis, meningeal metastasis, primary brain cancer or glioma, etc., and has good bioavailability, which is of great significance for further research on the efficacy of such solid drugs.

The present invention relates to crystalline forms of azithromycin derivatives, and the pharmaceutical formulations and therapeutic uses thereof, specifically salts, for example, crystalline forms, of the macrolide, (2S,3R,4S,6R)-4-(dimethylamino)-2-[[(2R,3S,4R,5R,8R,10R,11R,125,135,14R)-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-6-methyl-tetrahydropyran-3-yl]benzoate), in particular, the tartrate, oxalate and naphthalene di-sulphonate salts.

To provide treprostinil derivatives that can act as prodrugs of treprostinil.SOLUTION: A compound of formula (I), or a pharmaceutically acceptable salt thereof or the like. Wherein R1 and R2 are independently hydrogen, alkylcarbonyl, alkoxyalkylcarbonyl, and the like, with the proviso that R1 and R2 are not both hydrogen, and -OR1 and -OR2 do not both form acetates, benzoates, and the like; ) SELECTED DRAWING: None

Disclosed are salts of benzoic acid and prodrugs thereof for slowing the progression of or reducing the severity of a symptom associated with a nervous system injury in a subject.

The present invention provides methods of preparing compound of Formula (I), wherein the compounds are represented by the structure of Formula (I):wherein:R1 each is independently F, Cl, Br, I, OCH3, CN or NO2;R2 each is independently identical or different C1-C5 alkyl;n1 is an integer between 1 and 5; andn2 is an integer between 1 and 4.In addition, the present invention provides a compound represented by the following structures:wherein X comprises:chloride, acetate, adipate, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydroiodide, maleate, 2-hydroxyethanesulfonate, lactate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, sulfonate, tartrate, thiocyanate, toluenesulfonate, or undecanoate salt, or any combination thereof.

A pest control composition includes from about 4 wt% to about 10 wt % of sodium lauryl sulfate; a C5 to C9 hydrotropic salt, especially salts of benzoic acid or of sorbic acid; from about 1 wt% to about 12 wt% of one or more active ingredients chosen from corn mint oil, peppermint oil, spearmint oil, rosemary oil, thyme oil, citronella oil, clove oil, cedarwood oil, cinnamon oil, geranium oil, eugenol, 2-phenylethyl propionate, menthol, menthone, thymol, carvone, camphor, methyl salicylate, p-cymene, linalool, geraniol, cinnamyl acetate, cinnamic alcohol, cinnamaldehyde, citronellol, eucalyptol / l,8-cineole, alpha¬ pinene, bornyl acetate, gamma-terpinene, or combinations thereof; and from about 60 wt% to about 95 wt% of water. The ratio of hydrotropic salt to sodium lauryl sulfate of from about 0.15 to about 0.9. The pest control composition exhibits a receding contact angle of less than 20 degrees. A method of controlling weeds using the pest control composition..

Synthetic kava analog compounds of formula I are disclosed. Specifically, kava analogs of the structural type 3-oxoclclohex-1-en-1-yl benzoates, and corresponding benzamides are disclosed. The compounds of the within invention are useful, in the inhibition of cytokine TNF-α, the management of chronic inflammation such as but not limited to Porphyromonas gingivalis induced periodontitis, and in infective arthritis, either as compounds, pharmaceutically acceptable salts (when appropriate), pharmaceutical composition ingredients, whether or not in combination with other anti-inflammatory active pharmaceutical ingredients. Methods of treating chronic inflammation such as periodontitis and infective arthritis are also disclosed.